Diabetic peripheral arterial
atherosclerosis is one of the important characteristics of
diabetic foot syndrome.
Apolipoprotein (
Apo A-IV) participates in various physiological processes, and animal studies have shown that it has roles of anti-
atherosclerosis, prevention of platelet aggregation and
thrombosis.
Apo A-IV glycosylation is closely related to the occurrence and development of diabetic peripheral
atherosclerosis. This study aimed to explore the mechanism of diabetic peripheral arterial lesions caused by glycosylated
Apo A-IV.
Type 2 diabetes mellitus (T2DM) and T2DM with
diabetic foot patients (T2DM-F; n = 45, 30) were enrolled in this study, and individuals without diabetes (n = 35) served as normal controls (NC). In T2DM group, serum
Apo A-IV content was higher than those in NC and T2DM-F group, as
carboxymethyl lysine (CML) glycosylation of
Apo A-IV in mixed serum from T2DM-F group was identified to be more significant than those in two other groups. Within a microfluidic arterial chip model,
Apo A-IV from T2DM and T2DM-F group significantly increased transcription and
protein levels of
tumor necrosis factor alpha (TNF-α) in chip arteries, and CML expression was observed in T2DM-F group, which were associated with increased
nuclear receptor subfamily 4 group A member 3 (NR4A3) expression. Recombinant human
Apo A-IV could reverse the stimulating effect of serum
Apo A-IV from T2DM-F group on TNF-α expression, and NR4A3 blocking
peptide downregulated TNF-α expression by inhibiting NR4A3 expression. In the chip arteries,
Apo A-IV from T2DM and T2DM-F increased TNF-α expression and turn them into a pre-atherosclerotic state, which might be one of the important mechanisms of glycosylated
Apo A-IV to induce diabetic peripheral arterial lesions and eventually lead to
diabetic foot.